Home MARKET Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

by NORTH CAROLINA DIGITAL NEWS




Shares of Praxis Precision Medicines hit their highest intraday level since March 2022.



Source link

Related Posts